Scilex Holding (SCLX) Interest & Investment Income (2021 - 2022)
Scilex Holding (SCLX) recorded quarterly Interest & Investment Income of $459114.0 in Q3 2022, up 125.16% quarter-over-quarter from $203904.0 in Q2 2022, and up 25491.64% on a YoY basis from N/an in Q3 2021.
Scilex Holding (SCLX) Interest & Investment Income (2021 - 2022) Analysis & Trends
Scilex Holding's Interest & Investment Income history runs 2 years deep, the most recent figure standing at $459114.0 for Q3 2022.
- In Q3 2022, Interest & Investment Income rose 25491.64% year-over-year to $459114.0; the TTM figure through Sep 2022 stood at $667706.0 (changed N/A YoY), while the FY2021 annual figure was $30739.0, changed N/A from the prior year.
- Interest & Investment Income was $459114.0 for Q3 2022 at Scilex Holding, up from $203904.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $459114.0 in Q3 2022 to a low of $1794.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,162,528.78 Bn | 93,162,523.82 Bn | 7.76 Bn | 29.66 Mn |
| 2 | Eli Lilly | 1,017.87 Bn | 1,012.58 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 575.51 Bn | 553.46 Bn | 15.96 Bn | 229.00 Mn |
| 4 | AbbVie | 400.43 Bn | 391.08 Bn | 10.78 Bn | -645.00 Mn |
| 5 | Merck | 294.19 Bn | 288.54 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.41 Bn | 170.37 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 150.97 Bn | 143.24 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.75 Bn | 132.97 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 113.35 Bn | 102.90 Bn | 8.07 Bn | - |
| 10 | Scilex Holding | 57.99 Mn | -91.94 Mn | 4.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 459,114.00 |
| Jun 30, 2022 | 203,904.00 |
| Mar 31, 2022 | 1,955.00 |
| Dec 31, 2021 | 2,733.00 |
| Sep 30, 2021 | 1,794.00 |
| Jun 30, 2021 | 6,791.00 |
| Mar 31, 2021 | 19,421.00 |